Abstracts tagged "interstitial lung disease"

Abstract Number: 1148 • ACR Convergence 2025
Interstitial Lung Disease in MCTD: A Retrospective Cohort Study at a Large Tertiary Medical Center
Alana Haussmann¹ and Elizabeth Volkmann², ¹University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Mixed connective tissue disease (MCTD) is a rare autoimmune condition defined by the presence of anti-U1-ribonucleoprotein (RNP) antibodies and clinical features of at least…
Abstract Number: 0510 • ACR Convergence 2025
A risk estimation tool for clinical practice to improve early ILD detection in Sjögren Disease
Anna-Maria Hoffmann-Vold¹, Kastriot Kastrati², Marco Sprecher³, Emily Violette Langballe¹, Phuong Diep¹, Havard Fretheim¹, Helena Andersson¹, Paul Studenic⁴, Bojana Müller-Durovic³, Cathrine Brunborg¹, Cosimo Bruni⁵, Christian Clarenbach³, Thomas Frauenfelder⁶, Trond Mogens Aaløkken¹, Natasha Moe¹, Helmut Prosch⁴, Helga Radner², Øyvind Molberg⁷ and Oliver Distler⁸, ¹Oslo University Hospital, Oslo, Norway, ²Department of Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ³Univeristy Hospital Zurich, Zurich, Switzerland, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁶Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Zurich, Switzerland, ⁷Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) affects 10-15% of Sjögren disease (SjD) patients, leading to increased morbidity and reduced survival. The true prevalence may be higher…
Abstract Number: 2474 • ACR Convergence 2025
Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected
Carlos Valera Ribera¹, JUAN JOSE ALEGRE SANCHO², Ivan Castellvi³, Marta Ibañez⁴ and Javier Narváez⁵, ¹Hospital Universitario Doctor Peset, València, Spain, ²Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ³Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁴Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Anticentromere antibody (ACA)-positive interstitial lung disease (ILD) in systemic sclerosis (SSc) is traditionally considered less aggressive than anti-topoisomerase I (ATA)-positive ILD. However, its clinical…
Abstract Number: 2074 • ACR Convergence 2025
Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients
Sergio Maldonado Chaar¹ and Kelly Corbitt², ¹University of Miami/Jackson Health, Miami, FL, ²University of Miami Miller School of Medicine, El Portal, FL
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA-5) antibody positivity in dermatomyositis (DM) is often associated with development of interstitial lung disease (ILD), with factors such as…
Abstract Number: 1862 • ACR Convergence 2025
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis-associated interstitial lung disease identifies novel associated loci and potential progression biomarkers
Carlos de la Rosa Báez¹, Carlos Rangel Peláez¹, Inmaculada Rodríguez Martín¹, Martin Kerick¹, Alfredo guillen-del-castillo², Carmen Pilar Simeon³, Jose Luis Callejas⁴, Alexandre Voskuijl⁵, Alexander Kreuter⁶, Oliver Distler⁷, Susanna Proudman⁸, Mandana Nikpour⁹, Nicolas Hunzelmann¹⁰, Jeska de Vries-Bouwstra¹¹, Ariane Herrick¹², Yannick Allanore¹³, Lorenzo Beretta¹⁴, Maureen Mayes¹⁵, Christopher Denton¹⁶, Shervin Assassi¹⁷, Javier Martin¹ and Marialbert Acosta-Herrera¹, ¹Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain, ²Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain, ³Department of Internal Medicine, Hospital Universitario Vall d’Hebron, Barcelona, Spain, ⁴Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ⁶Department of Dermatology, Venereology, and Allergology, Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, Germany, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ⁸Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁹University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia, ¹⁰Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany, ¹¹Leiden University Medical Center, Leiden, Netherlands, ¹²The University of Manchester, UK, Aberdeen, United Kingdom, ¹³Department of Rheumatology, Université Paris Cité UFR de Médecine, Paris, France, ¹⁴Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ¹⁵UT Health Houston Division of Rheumatology, Houston, TX, ¹⁶University College London, UK, London, United Kingdom, ¹⁷Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: The main causes of death in systemic sclerosis (SSc) are pulmonary complications such as SSc-associated interstitial lung disease (SSc-ILD). SSc-ILD is highly heterogeneous and…
Abstract Number: 1577 • ACR Convergence 2025
Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Luc Mouthon¹, David Launay², Sylvie leroy³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Emmanuel Bergot⁶, Boris Bienvenu⁷, Benjamin Chaigne¹, Pascal Cohen⁸, Bruno Crestani⁹, Anca Corondan¹⁰, bertrand Dunogue¹, Christian Lavigne¹¹, Jonathan London¹², Jean-Marc Naccache¹⁰, Gabriel Baron¹³, Alexis REGENT¹⁴, Benjamin Terrier¹⁵, Zahir AMOURA¹⁶, Charles Marquette¹⁰ and Philippe Ravaud¹³, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ³AP HP, Paris, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Caen, France, ⁷Saint Joseph Hospital, Marseille, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁹CHU, Paris, France, ¹⁰NA, Paris, France, ¹¹CHU, Angers, France, ¹²Hôpital Croix-Saint-Simon, Paris, France, ¹³Hôtel-Dieu, Université Paris Cité,, Paris, France, ¹⁴Hopital Cochin, Paris, France, ¹⁵Cochin Hospital, Paris, France, ¹⁶APHP, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Randomized controlled trials favoured the use of cyclophosphamide…
Abstract Number: 1255 • ACR Convergence 2025
Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
Reena Yaman¹, Lisa Balistreri², Maximiliano Diaz Menindez³, Sehreen Mumtaz¹, Megan Sullivan³, Alexander Hochwald¹ and Florentina Berianu¹, ¹Mayo Clinic Florida, Jacksonville, FL, ²Lee Health, Cape Coral, FL, ³Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Pulmonary disease is present in most sarcoidosis cases with up to 10% of patients progressing to advanced lung disease.1 Pulmonary sarcoidosis accounted for 2.5%…
Abstract Number: 1063 • ACR Convergence 2025
Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Farheen Malik¹, Jawad Ahmed², Mandar Shah¹, Ritika Uttam³ and Muhammad Fahimuddin¹, ¹Jacobi Medical Center, Bronx, NY, NY, ²Northwest Health Porter, Valpraiso, IN, ³Jacobi Medical Center, Bronx, NY
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease affecting up to 1.0% of the US population. RA is most commonly associated with synovial inflammation…
Abstract Number: 0465 • ACR Convergence 2025
Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Suchita Nety¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Qianru Zhang¹, Nancy Shadick⁵, Michael Weinblatt⁶, Liya Sisay Getachew⁷, Gregory McDermott⁸ and Jeffrey Sparks⁷, ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham & Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women's Hospital, Brookline, MA
Background/Purpose: RA-associated lung diseases (RA-LD) such as RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR) are more common in men, but risk rises with…
Abstract Number: 2299 • ACR Convergence 2025
Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive interstitial lung disease associated with primary sjögren’s syndrome
Paula Estrada-Alarcón¹, Delia Reina², JUAN JOSE ALEGRE SANCHO³, Montserrat Roig Kim⁴, martí Aguilar-Coll⁵, Laia De Daniel Bisbe⁴, Aina Fabregat⁵, Monica Cubells⁵ and Javier Narváez⁶, ¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, ³Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁵Hospital Universitari de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To evaluate the real-world, long-term effectiveness of rituximab (RTX) as rescue therapy in patients with primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD).Methods: Multicentre observational…
Abstract Number: 2050 • ACR Convergence 2025
Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis
Sri Laxmi Priya Sunkara¹, Ravi Medarametla², Anjani Mahesh Kumar Cherukuri³, Rithish Nimmagadda⁴, Kaksha Parrikh⁵, Punith Chirumamilla⁶, Pranathi Bandarupalli⁷, Manoja Gullapalli⁸ and Naga Alekhya Garikipati⁹, ¹White river medical center, batesville, AR, ²Mamata Medical College, Guntur, Andhra Pradesh, India, ³Guntur Medical College, Guntur, Andhra Pradesh, India, ⁴One Brooklyn Health, New York, NY, ⁵Atlanticare regional medical center, New Jersey, ⁶Baptist Memorial Hospital North Mississippi, Oxford, MS, ⁷Mercy St Vincent Medical Center, Toledo, OH, ⁸University of Arkansas for Medical Sciences, Little Rock, AR, ⁹Mediciti Institute Of Medical Sciences, Hyderabad, India
Background/Purpose: Autoimmune–associated interstitial lung disease (A‑ILD) which includes Rheumatoid arthritis associated interstitial lung disease (RA-ILD), Systemic Sclerosis associated interstitial lung disease (SS-ILD), and others is…
Abstract Number: 1860 • ACR Convergence 2025
GLUT and FAPα as molecular imaging markers for interstitial lung disease in systemic sclerosis
Bo Broens¹, Conny van der Laken¹, Teodora Radonic¹, Douwe Mulder², esther Nossent¹, Yehya Al-Adwi², Tji Gan², Wim Timens², Alexandre Voskuijl³ and Jan Willem Duitman¹, ¹Amsterdam UMC, Amsterdam, Netherlands, ²UMCG Groningen, Groningen, Netherlands, ³Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: The clinical management of systemic sclerosis-associated interstitial lung disease (SSc-ILD) is challenging due to its heterogeneous progression. While recent studies have shown that pulmonary…
Abstract Number: 1576 • ACR Convergence 2025
Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
kyung-Ann Lee¹, Hyun-Sook Kim² and Boda Nam³, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ³Chung-Ang University Hospital, Seoul, Republic of Korea
Background/Purpose: Pulmonary fibrosis is a recognized sequela of severe COVID-19 pneumonia, but its additive impact on pre-existing interstitial lung disease (ILD)—particularly in patients with connective…
Abstract Number: 1220 • ACR Convergence 2025
Predictors of Progressive Pulmonary Fibrosis in Idiopathic Inflammatory Myopathies : a Retrospective Study of 502 Cases
Wei Bian¹, Jian Hao¹, Na zhang¹, Xiaojing Zhang¹, Fumin Qi¹, Yin Zhao² and Wei Wei¹, ¹Tianjin Medical University General Hospital, Tianjin, China (People's Republic), ²Affiliated Hospital of Yunnan University, Yunnan, China (People's Republic)
Background/Purpose: Interstitial lung disease (ILD) in idiopathic inflammatory myopathies (IIM) causes worse prognosis. Some patients develop progressive pulmonary fibrosis (PPF) despite appropriate treatment. Identifying predictors…
Abstract Number: 1024 • ACR Convergence 2025
Mortality In Progressive Pulmonary Fibrosis Associated to Autoimmune Diseases: NEREA Registry
Marta Ruiz-Valdepeñas Almansa¹, CLARA DE MIGUEL², DALIFER FREITES³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Olga Sanchez Pernaute⁵, fredeswinda Romero-Bueno⁶, Mª Jesus Rodriguez-Nieto⁷, Rosalia Laporta⁸, Hilda Godoy Tundidor⁹, Jesús Loarce¹⁰, Juan A Rigual¹¹ and lydia Abasolo Alcazar¹², ¹HOSPITAL CLINICO SAN CARLOS, Madrid, Spain, ²HOSPITAL CLINICO SAN CARLOS, Madrid, Madrid, Spain, ³Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Clinica Universidad de Navarra, Madrid, Madrid, Spain, ⁶University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ⁷Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁸Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁹Hospital Universitario puerta de hierro, Madrid, Spain, ¹⁰HOSPITAL RAMÓN Y CAJAL, MADRID, Madrid, Spain, ¹¹Hospital Ramón y Cajal, Madrid, Spain, ¹²IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Autoimmune interstitial lung disease (ILD) may arise in various autoimmune rheumatic diseases (ARD). Some patients develop ILD with systemic symptoms and autoantibodies without fulfilling…

« Previous Page
1
…
4
5
6
7
8
…
47
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].